Gastrointestinal Infections News

Although not currently licensed for patients undergoing dialysis for severe renal impairment, researchers found that treatment with Epclusa for hepatitis C was safe and effective in patients with end-stage renal disease.

Two adults with weakened immune systems who received investigational fecal microbiota transplantations developed invasive infections caused by extended-spectrum beta-lactamase-producing Escherichia coli, according to an FDA press release.

Patients who received interferon-based antiviral therapy for chronic hepatitis C had a significantly lower incidence rate of Parkinson’s disease compared with untreated patients, according to an analysis published in JAMA Neurology.

Today, June 7, marks the first U.N. World Food Safety Day.

An investigational vaccine for the prevention of Clostridioides difficile infection was safe, well-tolerated and immunogenic in healthy adults aged 65 to 85 years, according to findings from a phase 2 study published in Clinical Infectious Diseases.

A multifacility collaborative initiative implemented among acute-care hospitals in Orange County, California, resulted in a statistically significant 4% monthly decrease in hospital-onset Clostridioides difficile infection, or CDI, and a statistically significant 2% decrease in community-onset CDI, researchers reported in Infection Control & Hospital Epidemiology.

Researchers found that treatment with a combination of Viread and GS-4774, a yeast-based therapeutic vaccine, increased hepatitis B-specific T cell immune response in untreated patients with chronic hepatitis B.

Infectious disease physicians in the United States do not commonly screen patients for asymptomatic carriage of Clostridioides difficile, according to results from a nationwide survey.

Gilead Sciences Canada awarded a series of HCV Micro-Elimination Grants to 11 organizations focused on identifying individuals with hepatitis C in high-risk hard-to-reach populations throughout Canada and linking them to care, according to a press release.

Researchers identified a common polymorphism and a rare variant combination in hepatitis C genotype 3 that are responsible for a reduced response to Sovaldi, according to a study published in Gastroenterology.